Glioblastoma – Radiotherapy Plus Temodar With Nimotuzumab

Background about Glioblastoma and the new drug

Glioblastoma (GBM) has a poor prognosis, and patients with Epidermal Growth Factor Receptor (EGFR) amplification have an even worse prognosis.

Nimotuzumab is an EGFR monoclonal antibody thought to play a significant role in the treatment of GBM.

It is approved in India, China, and other countries for Head and Neck cancer.

The Epidermal Growth Factor Receptor (EGFR) is expressed to varying degrees in more than 40% of gliomas.

Activation of EGFR signaling causes uncontrolled tumor proliferation.

However, targeted therapy against EGFR amplification has emerged as one of the therapeutic options for gliomas.

In this article we will present a study that evaluates the clinical efficacy and safety of Nimotuzumab in Glioblastoma.

About the Study

A total of 56 newly diagnosed patients with EGFR-positive Glioblastoma were included.

The patients were divided into 2 groups:

Radiotherapy + Temodar + Nimotuzumab (39 patients) and Radiotherapy + Temodar (17 patients).

Patients in both groups underwent tumor resection surgery.

Time until disease progression (also called Progression-Free Survival, PFS), Survival and side effects were assessed.


The median time until disease progression was 12.4 months and 8.2 months in the 2 groups, respectively

The median Survival was 27.3 months and 16.7 months, respectively

In patients with unmethylated MGMT, the median time until disease progression and Survival were significantly better in patients treated with Nimotuzumab:

The median time until disease progression was 19.3 vs 6.7 months

The median Survival was 20.2 vs 13.8 months

During the treatment period, no significant difference in toxicity was noted between the 2 groups.

Conclusion for Newly Diagnosed Glioblastoma Patients

This study suggests the efficacy of Nimotuzumab combined with radiotherapy and Temodar in patients with newly diagnosed EGFR-positive GBM, and specifically those with unmethylated MGMT promoter.

Nimotuzumab demonstrated good safety and tolerability.

Talk to us so see if we can help you to actually get the most advanced treatments


Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

Read more about Glioblastoma >>

Glioblastoma - Radiotherapy Plus Temodar With Nimotuzumab
Glioblastoma – Radiotherapy Plus Temodar With Nimotuzumab

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics